ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

被引：0
|
作者：
Flinn, Ian W.
Jacobson, Caron Alyce
Nastoupil, Loretta J.
Morschhauser, Franck
Davies, Andrew
Buske, Christian
Corradini, Paolo
Guillermo, Armando Lopez
Reshef, Ran
Parameswaran, Vinod
Sehgal, Alison
Tees, Michael Timothy
Lui, Christine
Xue, Wei
Beygi, Sara
Grechko, Nikolay
Bolsue, Pisita
Giovanetti, Alessandro
To, Christina Ann
Nahas, Myrna
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Lille, Ctr Hosp Univ, Lille, France
[5] Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England
[6] Univ Hosp Ulm, Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Univ Barcelona, Barcelona, Spain
[9] Columbia Univ, Med Ctr, New York, NY USA
[10] Avera Med Grp Hematol Transplant & Cellular Thera, Sioux Falls, SD USA
[11] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[12] Colorado Blood Canc Inst, Denver, CO USA
[13] Kite, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7579
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)
    Elsawy, Mahmoud
    Chavez, Julio C.
    Avivi, Irit
    Larouche, Jean-Francois
    Wannesson, Luciano
    Cwynarski, Kate
    Osman, Keren
    Davison, Kelly
    Rudzki, Jakob D.
    Dahiya, Saurabh
    Dorritie, Kathleen
    Jaglowski, Samantha
    Radford, John
    Morschhauser, Franck
    Cunningham, David
    Garcia-Sancho, Alejandro Martin
    Tzachanis, Dimitrios
    Ulrickson, Matthew L.
    Karmali, Reem
    Kekre, Natasha
    Thieblemont, Catherine
    Enblad, Gunilla
    Dreger, Peter
    Malladi, Ram
    Joshi, Namita
    Wang, Wei-Jhih
    Solem, Caitlyn T.
    Snider, Julia Thornton
    To, Christina
    Kersten, Marie Jose
    BLOOD, 2021, 138
  • [22] Interim Analysis of ZUMA-5: a Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
    Jacobson, Caron
    Chavez, Julio
    Sehgal, Alison
    William, Basem
    Munoz, Javier
    Salles, Gilles
    Casulo, Carla
    Munshi, Pashna
    Maloney, David
    de Vos, Sven
    Reshef, Ran
    Leslie, Lori
    Yakoub-Agha, Ibrahim
    Oluwole, Olalekan
    Fung, Henry Chi Hang
    Plaks, Vicki
    Yang, Yin
    Lee, Jennifer
    Avanzi, Mauro
    Neelapu, Sattva
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S20 - S21
  • [23] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
    Topp, Max S.
    van Meerten, Tom
    Wermke, Martin
    Lugtenburg, Elly J.
    Minnema, Monique C.
    Song, Kevin W.
    Thieblemont, Catherine
    Jiang, Yizhou
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non- Hodgkin Lymphoma (iNHL)
    Neelapu, Sattva S.
    Chavez, Julio C.
    Sehgal, Alison R.
    Epperla, Narendranath
    Ulrickson, Matthew L.
    Bachy, Emmanuel
    Munshi, Pashna N.
    Casulo, Carla
    Maloney, David G.
    de Vos, Sven
    Reshef, Ran
    Leslie, Lori A.
    Oluwole, Olalekan O.
    Yakoub-Agha, Ibrahim
    Khanal, Rashmi
    Rosenblatt, Joseph D.
    Sherman, Marika
    Dong, Jinghui
    Giovanetti, Alessandro
    Yang, Yin
    Lui, Christine
    Bashir, Zahid
    Jung, A. Scott
    Jacobson, Caron
    BLOOD, 2021, 138
  • [25] Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
    Locke, Frederick L.
    Oluwole, Olalekan O.
    Kuruvilla, John
    Thieblemont, Catherine
    Morschhauser, Franck
    Salles, Gilles
    Rowe, Steven P.
    Vardhanabhuti, Saran
    Filosto, Simone
    To, Christina
    Cheng, Paul
    Schupp, Marco
    Korn, Ronald
    Kersten, Marie Jose
    BLOOD, 2022, 140
  • [26] ZUMA-7: RANDOMIZED PHASE 3 ESSAY OF AXICABTAGEN CILOLEUCEL (AXI-CEL) VS STANDARD TREATMENT (SOC) IN PATIENTS WITH LYMPHOMA B DIFFUSE OF LARGE CELLS IN RECYCLED/REFRACTORY (R/R DLBCL)
    Caballero, M. D.
    Cwynarski, K.
    Dreger, P.
    Thieblemont, C.
    Vandenberghe, P.
    Zinzani, P. L.
    Mueller, A.
    Greinix, H.
    Avivi, I
    Enblad, G.
    Locke, F. L.
    Yang, Y.
    Brock, K.
    Cheng, P.
    Kersten, M. J.
    HAEMATOLOGICA, 2018, 103 : 359 - 359
  • [27] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J.
    Sorensen, Sonja
    Dorman, Emily
    BLOOD, 2021, 138
  • [28] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
    Hathway, Joanne
    Purdum, Anna
    Lin, Vincent W.
    Cyr, Philip
    Westin, Jason
    Jensen, Ivar
    BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
  • [29] Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
    Plaks, Vicki
    Chou, Justin
    Goyal, Lovely
    Zhang, Wangshu
    Salunkhe, Shruti
    Sehgal, Alison R.
    Chavez, Julio C.
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Avanzi, Mauro P.
    Rossi, John M.
    Bot, Adrian
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
    Sharp, John
    Strati, Paolo
    Bhatta, Subodh
    Huang, Jennifer J.
    Thomas, Colin
    Reef, Daniel K.
    Gorzewski, Alexander
    Reinert, Catherine
    Teferra, Andinet
    Pelcovits, Ari
    Ollila, Thomas
    Maakaron, Joseph E.
    Kamdar, Manali K.
    Fitzgerald, Lindsey
    Karmali, Reem
    Grover, Natalie
    Barta, Stefan K.
    Voorhees, Timothy
    Shadman, Mazyar
    Ahmed, Sairah
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2377 - 2378
12345